Overview
Reveal is developing gadolinium-free MRI contrast agents designed to improve safety and deepen insight for medical imaging.
Our lead product, RVP-001, is designed as a direct substitute for current MRI contrast agents, avoiding the risks posed by gadolinium accumulation in all patients from all current contrast agents. RVP technology provides a platform for precision imaging of fibrosis, thrombosis, lymph nodes, and more: these agents will inform the use of targeted therapeutics and guide personalized medicine.
Reveal was founded in 2016; our patented technology was invented by Peter Caravan and Eric Gale at Harvard Medical School / MGH.